## **AMENDMENTS**

## IN THE CLAIMS:

Under 37 C.F.R. § 1.121(c), please amend the claims as follows:

- 1. (Canceled)
- 2. (Currently amended) The method of claim 1 wherein the agonist is A method for treating a patient with Parkinson's disease resulting from a dopamine-related dysfunction, said method comprising the steps of:

administering to the patient a full  $D_1$  agonist selected from the group consisting of dinapsoline, dinoxyline, dihydrexidine, analogs and derivatives of said agonists, and combinations thereof, wherein said agonist has a half-life of less than 6 hours and wherein said agonist is administered periodically at a dose resulting in a first tissue concentration of agonist capable of activating  $D_1$  dopamine receptors to produce a therapeutic effect; and

reducing said agonist dose at least once every 24 hours to obtain a second lower tissue concentration of agonist wherein said second concentration of agonist results in suboptimal activation of  $D_1$  dopamine receptors for a period of time sufficient to prevent induction of tolerance.

- 3. (Canceled)
- 4. (Currently amended) The method of claim <u>1-2</u> wherein said agonist is administered parenterally.
- 5. (Original) The method of claim 4 wherein said parenteral administration route is selected from the group consisting of intradermal, subcutaneous, intramuscular, intraperitoneal, intrathecal, and intravenous administration.
- 6. (Original) The method of claim 4 wherein said parenteral administration is achieved using a pulsatile release dosage form.
- 7. (Original) The method of claim 4 wherein said parenteral administration is achieved using a metering pump.
- 8. (Currently amended) The method of claim 1-2 wherein said agonist is administered intranasally.
- 9. (Currently amended) The method of claim 1–2 wherein said agonist is administered orally.
- 10. (Currently amended) The method of claim <u>1-2</u> wherein said agonist is administered in combination with an antioxidant.

- 11. (Currently amended) The method of claim 1–2 wherein the period of time for reducing said agonist dose to obtain said second tissue concentration of agonist is at least one hour per each 24-hour dosing period.
- 12. (Currently amended) The method of claim 4-2 wherein the period of time for reducing said agonist dose to obtain said second tissue concentration of agonist is about one hour to about four hours per each 24-hour dosing period.
- 13. (New) The method of claim 2 wherein the reducing step includes reducing said agonist dose at least twice every 24 hours to obtain a second lower tissue concentration of agonist.
- 14. (New) The method of claim 13 wherein the period of time for reducing said agonist dose to obtain said second tissue concentration of agonist is at least one hour per\_each dosing period.
- 15. (New) The method of claim 13 wherein the period of time for reducing said agonist dose to obtain said second tissue concentration of agonist is about one hour to about four hours per each dosing period.